A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma

Zemann, B.I.; Moore, A.S.; Rand, W.M.; Mason, G.; Ruslander, D.M.; Frimberger, A.E.; Wood, C.A.; L'Heureux, D.A.; Gliatto, J.; Cotter, S.M.

Journal of Veterinary Internal Medicine 12(6): 465-470


ISSN/ISBN: 0891-6640
PMID: 9857340
DOI: 10.1111/j.1939-1676.1998.tb02151.x
Accession: 003018928

Download citation:  

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Ninety-eight dogs with lymphoma treated with a 5-drug combination chemotherapy regimen (vincristine, L-asparaginase, cyclophosphamide, doxorubicin, prednisone [VELCAP-L]) were evaluated for pretreatment characteristics predictive for response and remission duration. The complete remission rate was 69%, with a median remission duration of 55 weeks. Dogs with advanced stage of disease, constitutional signs, dogs that were older, and dogs that were dyspneic were less likely to achieve remission. Once in remission, small dogs and dogs without pretreatment thrombocytopenia were likely to have longer remission duration. Toxicoses were frequent, but rarely fatal, and no predictitive factors were found for a dog developing toxicoses. VELCAP-L is an effective treatment for dogs in stage I-III lymphoma, particularly in young, small animals.

A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma